Department of Dermatology, The First Affiliated Hospital of Kangda College of Nanjing Medical University/The First People's Hospital of Lianyungang/The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, China.
Department of Geriatrics, The Third People's Hospital of Kunshan City, Kunshan, China.
J Cell Mol Med. 2024 Jul;28(14):e18570. doi: 10.1111/jcmm.18570.
Melanoma, a highly malignant tumour, presents significant challenges due to its cellular heterogeneity, yet research on this aspect in cutaneous melanoma remains limited. In this study, we utilized single-cell data from 92,521 cells to explore the tumour cell landscape. Through clustering analysis, we identified six distinct cell clusters and investigated their differentiation and metabolic heterogeneity using multi-omics approaches. Notably, cytotrace analysis and pseudotime trajectories revealed distinct stages of tumour cell differentiation, which have implications for patient survival. By leveraging markers from these clusters, we developed a tumour cell-specific machine learning model (TCM). This model not only predicts patient outcomes and responses to immunotherapy, but also distinguishes between genomically stable and unstable tumours and identifies inflamed ('hot') versus non-inflamed ('cold') tumours. Intriguingly, the TCM score showed a strong association with TOMM40, which we experimentally validated as an oncogene promoting tumour proliferation, invasion and migration. Overall, our findings introduce a novel biomarker score that aids in selecting melanoma patients for improved prognoses and targeted immunotherapy, thereby guiding clinical treatment decisions.
黑色素瘤是一种高度恶性的肿瘤,由于其细胞异质性而带来重大挑战,但皮肤黑色素瘤在这方面的研究仍然有限。在这项研究中,我们利用来自 92521 个细胞的单细胞数据来探索肿瘤细胞景观。通过聚类分析,我们确定了六个不同的细胞簇,并使用多组学方法研究了它们的分化和代谢异质性。值得注意的是,细胞追踪分析和伪时间轨迹揭示了肿瘤细胞分化的不同阶段,这对患者的生存有影响。通过利用这些簇中的标记物,我们开发了一种肿瘤细胞特异性的机器学习模型(TCM)。该模型不仅预测了患者的预后和对免疫治疗的反应,还区分了基因组稳定和不稳定的肿瘤,并识别了炎症(“热”)和非炎症(“冷”)肿瘤。有趣的是,TCM 评分与 TOMM40 强烈相关,我们通过实验验证了 TOMM40 是一种促进肿瘤增殖、侵袭和迁移的致癌基因。总的来说,我们的研究结果引入了一种新的生物标志物评分,可以帮助选择黑色素瘤患者进行改善预后和靶向免疫治疗,从而指导临床治疗决策。